Functional status and health-related quality of life among allogeneic transplant patients at hospital discharge: a comparison of sociodemographic, disease, and treatment characteristics
- 384 Downloads
The purpose of this paper is to report the findings of a study of hematopoietic cell transplant patients, describing the needs of allogeneic transplant patients at the time of discharge in regard to their functional status, quality of life (QOL), and caregiver information and comparing these needs across a number of sociodemographic, disease, and treatment characteristics. The findings of this study are part of a larger mixed-methods study, representing one data time point of the larger study.
This paper will discuss the baseline data collected at the time of discharge for 282 allogeneic transplant patients, which include sociodemographic data combined with disease, treatment, functional status, and QOL data to present a comprehensive portrait of the transplant patient at discharge.
Mean age was 48 years, males represented 52%, and 22% of the patients were Hispanic. The majority of the patients had acute leukemia (55%), were diagnosed within the last 3 years, and had matched unrelated (52%) transplants. The time from transplant to discharge averaged 30 days. Mean scores for QOL (scale = 1–10, with 10 = best QOL) included a low score of 5.7 for both psychological and social well-being, 6.3 for overall QOL, and 7.1 for both physical and spiritual well-being. Males had significantly higher QOL than females, as did non-Hispanics. Patients with Hodgkin’s disease had significantly lower overall QOL scores.
Our results highlight the physical, psychological, social, and spiritual challenges which present for patients and their caregivers at the time of hospital discharge following allogeneic transplant.
KeywordsAllogeneic transplant Discharge status Quality of life
- 1.The Medical College of Wisconsin IatNMDP (2011) Accessed April 19, 2011Google Scholar
- 7.Andrykowski M, McQuellon R (2004) Psychosocial issues in hematopoietic cell transplantation. In: Blume KB, SJF, Appelbaum FR (eds) Thomas’ hematopoietic cell transplantation, 3rd edn. Blackwell Science LTD, Malden, Massachusetts, pp 497–506Google Scholar
- 8.Horan JT, Logan BR, Agovi-Johnson MA, Lazarus HM, Bacigalupo AA, Ballen KK, Bredeson CN, Carabasi MH, Gupta V, Hale GA, Khoury HJ, Juckett MB, Litzow MR, Martino R, McCarthy PL, Smith FO, Rizzo JD, Pasquini MC (2011) Reducing the risk for transplantation-related mortality after allogeneic hematopoietic cell transplantation: how much progress has been made? J Clin Oncol 29(7):805–813. doi:10.1200/JCO.2010.32.5001 PubMedCrossRefGoogle Scholar
- 9.Pasquini MC, Wang Z (2009) Current use and outcome of hematopoietic stem cell transplantation: Part II- CIBMTR Summary Slides. CIBMTR Newsl 15(2):7–11Google Scholar
- 12.Grant M, Primary investigator (2005) RO1 CA 107446: a standardized nursing intervention protocol for HCT patients. National Cancer Institute, City of Hope Medical CenterGoogle Scholar
- 16.Grant M (1999) Assessment of quality of life following hematopoietic cell transplantation. In: Forman SJ, Blum KG, Thomas ED (eds) Hematopoietic cell transplantation, 2nd edn. Blackwell Science, Inc., pp 407–413Google Scholar
- 18.Lynch JC, Morris ME, Bociek G, Bierman PJ, Vose JM, Armitage JO (2003) Quality of life of non-Hodgkin’s lymphoma survivors. Poster session presented at the annual conference of the International Society for Quality of Life Research. Prague, Czech RepublicGoogle Scholar
- 20.Whedon M, Stearns D, Mills LE (1997) Quality of life of long-term cancer survivors. Oncol (Williston Park) 11(4):565–571Google Scholar
- 21.Morris AS, Lynch JC, Bociek G, Tarantolo S, Bierman PJ, Vose JM, Armitage JO (2003) Preliminary quality of life findings of patients undergoing hematopoietic stem cell transplant untilizing the City of Hope National Medical Center and Functional Assessment of Cancer Therapy Instruments. Clin Ther Supl D:D21–D22Google Scholar
- 24.Lee SJ, Loberiza FR, Antin JH, Kirkpatrick T, Prokop L, Alyea EP, Cutler C, Ho VT, Richardson PG, Schlossman RL, Fisher DC, Logan B, Soiffer RJ (2005) Routine screening for psychosocial distress following hematopoietic stem cell transplantation. Bone Marrow Transpl 35(1):77–83. doi:10.1038/sj.bmt.1704709 CrossRefGoogle Scholar
- 26.Flowers ME, Sullivan KM (2004) Management of patients undergoing marrow or blood stem cell transplantation. In: Atkinson K, RC, Ritz J, Fibbe W, Ljungman P, Brenner M (eds) Clinical bone marrow and blood stem cell transplantation. Cambridge University Press, Cambridge, UK, pp 313–336Google Scholar
- 27.Schmitz N (2004) Peripheral Blood Hematopoietic Cells for Allogeneic Transplantation. In: Blume KG, Fredrick SJF, Appelbaum R (eds) Thomas’ hematopoietic cell transplantation, 3rd edn. Blackwell Science Ltd, Malden, MassachusettesGoogle Scholar
- 28.Pavletic ZS, Bishop MR, Tarantolo SR, Martin-Algarra S, Bierman PJ, Vose JM, Reed EC, Gross TG, Kollath J, Nasrati K, Jackson JD, Armitage JO, Kessinger A (1997) Hematopoietic recovery after allogeneic blood stem-cell transplantation compared with bone marrow transplantation in patients with hematologic malignancies. J Clin Oncol 15(4):1608–1616PubMedGoogle Scholar
- 31.Peniket AJ, Ruiz de Elvira MC, Taghipour G, Cordonnier C, Gluckman E, de Witte T, Santini G, Blaise D, Greinix H, Ferrant A, Cornelissen J, Schmitz N, Goldstone AH (2003) An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transpl 31(8):667–678. doi:10.1038/sj.bmt.1703891 CrossRefGoogle Scholar
- 39.Allen J (2008) A third of young adults uninsured in 2008: U.S. report. WashingtonGoogle Scholar